MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- FRESENIUS KABI ONCO. - GSK PHARMA
FRESENIUS KABI ONCO. vs GSK PHARMA - Comparison Results
FRESENIUS KABI ONCO. Change
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
GSK PHARMA 
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Current Valuations
| FRESENIUS KABI ONCO. | GSK PHARMA | FRESENIUS KABI ONCO./ GSK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.1 | 52.1 | 42.5% | View Chart |
| P/BV | x | 3.1 | 11.0 | 28.4% | View Chart |
| Dividend Yield | % | 0.0 | 1.4 | - |
Financials
 FRESENIUS KABI ONCO.  GSK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| FRESENIUS KABI ONCO. Mar-13 |
GSK PHARMA Mar-19 |
FRESENIUS KABI ONCO./ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 176 | 3,595 | 4.9% | |
| Low | Rs | 79 | 1,253 | 6.3% | |
| Sales per share (Unadj.) | Rs | 37.7 | 184.7 | 20.4% | |
| Earnings per share (Unadj.) | Rs | 5.1 | 26.3 | 19.4% | |
| Cash flow per share (Unadj.) | Rs | 6.7 | 29.2 | 23.1% | |
| Dividends per share (Unadj.) | Rs | 0 | 20.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
| Book value per share (Unadj.) | Rs | 42.5 | 126.3 | 33.7% | |
| Shares outstanding (eoy) | m | 158.23 | 169.40 | 93.4% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.4 | 13.1 | 25.7% | |
| Avg P/E ratio | x | 25.0 | 92.2 | 27.1% | |
| P/CF ratio (eoy) | x | 18.9 | 83.1 | 22.8% | |
| Price / Book Value ratio | x | 3.0 | 19.2 | 15.6% | |
| Dividend payout | % | 0 | 76.1 | 0.0% | |
| Avg Mkt Cap | Rs m | 20,135 | 410,626 | 4.9% | |
| No. of employees | `000 | 1.2 | 5.0 | 23.2% | |
| Total wages/salary | Rs m | 703 | 5,372 | 13.1% | |
| Avg. sales/employee | Rs Th | 5,176.2 | 6,306.7 | 82.1% | |
| Avg. wages/employee | Rs Th | 610.4 | 1,083.1 | 56.4% | |
| Avg. net profit/employee | Rs Th | 699.6 | 898.0 | 77.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,963 | 31,281 | 19.1% | |
| Other income | Rs m | 18 | 1,023 | 1.8% | |
| Total revenues | Rs m | 5,981 | 32,304 | 18.5% | |
| Gross profit | Rs m | 1,430 | 6,009 | 23.8% | |
| Depreciation | Rs m | 258 | 486 | 53.1% | |
| Interest | Rs m | -26 | 6 | -433.3% | |
| Profit before tax | Rs m | 1,216 | 6,540 | 18.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -68 | 287 | -23.7% | |
| Tax | Rs m | 342 | 2,373 | 14.4% | |
| Profit after tax | Rs m | 806 | 4,454 | 18.1% | |
| Gross profit margin | % | 24.0 | 19.2 | 124.9% | |
| Effective tax rate | % | 28.1 | 36.3 | 77.5% | |
| Net profit margin | % | 13.5 | 14.2 | 94.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 5,102 | 20,061 | 25.4% | |
| Current liabilities | Rs m | 2,385 | 14,543 | 16.4% | |
| Net working cap to sales | % | 45.6 | 17.6 | 258.2% | |
| Current ratio | x | 2.1 | 1.4 | 155.0% | |
| Inventory Days | Days | 150 | 57 | 264.3% | |
| Debtors Days | Days | 113 | 14 | 805.7% | |
| Net fixed assets | Rs m | 5,148 | 14,343 | 35.9% | |
| Share capital | Rs m | 158 | 1,694 | 9.3% | |
| "Free" reserves | Rs m | 6,556 | 19,704 | 33.3% | |
| Net worth | Rs m | 6,732 | 21,398 | 31.5% | |
| Long term debt | Rs m | 952 | 2 | 47,610.0% | |
| Total assets | Rs m | 10,388 | 39,113 | 26.6% | |
| Interest coverage | x | -45.8 | 1,091.0 | -4.2% | |
| Debt to equity ratio | x | 0.1 | 0 | 151,337.3% | |
| Sales to assets ratio | x | 0.6 | 0.8 | 71.8% | |
| Return on assets | % | 7.5 | 11.4 | 65.8% | |
| Return on equity | % | 12.0 | 20.8 | 57.5% | |
| Return on capital | % | 14.6 | 31.9 | 45.7% | |
| Exports to sales | % | 74.5 | 0 | - | |
| Imports to sales | % | 24.8 | 0 | - | |
| Exports (fob) | Rs m | 4,441 | NA | - | |
| Imports (cif) | Rs m | 1,477 | NA | - | |
| Fx inflow | Rs m | 5,298 | 534 | 992.1% | |
| Fx outflow | Rs m | 1,772 | 7,091 | 25.0% | |
| Net fx | Rs m | 3,525 | -6,557 | -53.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,274 | 3,994 | 31.9% | |
| From Investments | Rs m | -1,204 | -1,433 | 84.0% | |
| From Financial Activity | Rs m | -196 | -3,584 | 5.5% | |
| Net Cashflow | Rs m | -126 | -1,023 | 12.3% | |
Share Holding
| Indian Promoters | % | 0.0 | 0.0 | - | |
| Foreign collaborators | % | 81.0 | 50.7 | 159.8% | |
| Indian inst/Mut Fund | % | 0.3 | 10.2 | 2.9% | |
| FIIs | % | 9.6 | 23.8 | 40.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 15.4 | 59.1% | |
| Shareholders | 42,599 | 102,036 | 41.7% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare FRESENIUS KABI ONCO. With: ABBOTT INDIA JUBILANT LIFE SCIENCES BIOCON IPCA LABS NATCO PHARMA
Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)
What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!
Related Views on News
GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)
Jul 24, 2019 | Updated on Jul 24, 2019For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)
May 21, 2019 | Updated on May 21, 2019For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)
Feb 5, 2019 | Updated on Feb 5, 2019For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)
Oct 23, 2018 | Updated on Oct 23, 2018For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)
Sep 19, 2019The India we knew is changing. Here's how you can benefit from this change.
The 5 Best Trading Opportunities I've Spotted(Profit Hunter)
Sep 13, 2019These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.
MoreFRESENIUS KABI ONCO. SHARE PRICE
Jan 2, 2014 (Close)
TRACK FRESENIUS KABI ONCO.
- Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON FRESENIUS KABI ONCO.
FRESENIUS KABI ONCO. - AJANTA PHARMA COMPARISON
COMPARE FRESENIUS KABI ONCO. WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.